Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORION: Amibegron in Major Depressive Disorder
NCT00252356Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2005
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of amibegron in major depressive disorder (MDD) (3 arms), sponsored by Sanofi. Primary endpoint: 17-item Hamilton Depression Rating Scale. Started Sep 2005; status: completed.
02
Drugs
amibegron
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00252356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00252356.